Hepatoprotective effect of pentoxifylline against D-galactosamine-induced hepatotoxicity in rats.
The present study was conducted to investigate effect of pentoxifylline (PTX) on acute liver injury caused by galactosamine (D-Gal) in rats and the underlying mechanism involved in this setting. Moreover, we attempted to compare its effect to the well-established hepatoprotective agent, silymarin (SYM). The rats were randomly assigned 5 groups, control, PTX-treated (100 mg/kg, 3 weeks), SYM-treated (100 mg/kg, 3 weeks) and their combination. Hepatic injury was induced by intraperitoneal single dose injection of D-Gal (800 mg/kg). Hepatic functions parameters, including serum albumin and alkaline phosphatase (ALP) levels were determined. Antioxidants enzyme activities such as superoxide dismutase (SOD), catalase (CAT) as well as lipid peroxides and hepatic total nitrites were measured. Besides, histopathological examination was also performed using portions of liver tissues. Results showed that the liver injury induced by D-Gal was improved in the three pretreated groups to variable extents. Pretreatment with PTX prevented D-Gal-induced reduction of antioxidant enzyme activities, SOD and CAT, and attenuated the elevated malonaldahyde (MDA) level in hepatic tissue as marker of lipid peroxidation. In addition, pretreatment with PTX resulted in an increase in hepatic triglycerides, normalization of nitric oxide level, and lowering serum ALP activity as well as inhibited the decreased serum albumin level caused by D-Gal. These biochemical changes were reflected on attenuation the structural alterations of the liver integrity. Collectively, our data suggest that PTX exhibits a potential hepatoprotective effect against D-Gal-induced hepatotoxicity and this effect might be attributed to its antioxidant properties.
Taye
Ashraf
A
Department of Pharmacology & Toxicology, Faculty of Pharmacy, Minia University, Egypt. Ashraf_taye70@yahoo.com
El-Moselhy
Mohamed A
MA
Hassan
Magdy K A
MK
Ibrahim
Hanaa M
HM
Mohammed
Aliaa F
AF
D000469:Alkaline Phosphatase / Q000097:blood; D000818:Animals; D002374:Catalase / Q000378:metabolism; D056486:Chemical and Drug Induced Liver Injury / Q000378:metabolism* / Q000473:pathology / Q000517:prevention & control*; D004195:Disease Models, Animal; D005688:Galactosamine / Q000009:adverse effects*; D007274:Injections, Intraperitoneal; D008054:Lipid Peroxides / Q000378:metabolism; D008099:Liver / Q000378:metabolism / Q000473:pathology; D008297:Male; D008315:Malondialdehyde / Q000378:metabolism; D010431:Pentoxifylline / Q000008:administration & dosage / Q000627:therapeutic use*; D010726:Phosphodiesterase Inhibitors / Q000008:administration & dosage / Q000627:therapeutic use*; D020011:Protective Agents / Q000008:administration & dosage / Q000627:therapeutic use; D051381:Rats; D011919:Rats, Inbred Strains; D012709:Serum Albumin / Q000378:metabolism; D012838:Silymarin / Q000008:administration & dosage / Q000627:therapeutic use; D013482:Superoxide Dismutase / Q000378:metabolism
D008054:Lipid Peroxides; D010726:Phosphodiesterase Inhibitors; D020011:Protective Agents; D012709:Serum Albumin; D012838:Silymarin; D008315:Malondialdehyde; D005688:Galactosamine; D002374:Catalase; D013482:Superoxide Dismutase; D000469:Alkaline Phosphatase; D010431:Pentoxifylline